Sonova’s Strategic Reset: Selling Sennheiser Consumer to Focus on Hearing Care Core

The core expectation arbitrage at Sonova is clear. The market had priced in a solid growth trajectory, but the official guidance signals a reset. For the full year 2025/2026, the company's formal revenue growth forecast is a range of 5% to 9%, with a midpoint of 7%. CEO Eric Bernard has now stated that actual growth will come at the lower end of that range. That's a direct beat-down from the midpoint, framing this as a guidance reset.

This move follows a period where growth was likely priced in too optimistically. The 2024/25 financial year saw sales rise 6.6% in Swiss francs, but the acceleration was driven by successful product launches and a strong second half. The final months of that year, however, revealed a vulnerability: a slowdown in the US private hearing aid market hampered overall development. This late-year pressure likely pressured the outlook for the new fiscal year, forcing a strategic reassessment.

The company is taking time to review its midterm goals, a process that began with a new CEO and other leadership changes. This pause is the strategic pivot. It indicates management is stepping back to recalibrate, likely after a period where the market's whisper number for Sonova's growth had climbed higher than the underlying market conditions could support. The guidance reset is the first tangible sign of that new reality.

The Strategic Pivot: Selling Sennheiser Consumer

The potential sale of the Sennheiser consumer unit is the clearest signal yet of Sonova's strategic pivot. This move is not a retreat from consumer audio, but a targeted reset to focus capital and attention on its core hearing care business. The rationale is straightforward: after a five-year integration, the standalone value and strategic fit of the consumer electronics unit are now under intense scrutiny.

Sonova acquired Sennheiser Consumer in 2021 with a clear ambition: to leverage the premium brand's reputation in headphones and soundbars to expand its portfolio and create new consumer touchpoints under the joint Sennheiser brand umbrella. The goal was to combine Sennheiser's audio expertise with Sonova's audiological know-how, particularly in emerging markets like speech-enhanced hearables. Yet, CEO Eric Bernard's current directive is to look at all business areas in detail as part of a midterm review. This broad mandate places the Sennheiser unit squarely in the crosshairs, testing whether its growth trajectory and margin profile still align with the company's new, more conservative forward view.

This mirrors a broader sector trend of portfolio pruning. Sonova's biggest competitor, Demant, sold its hearing implants business last year, a move that sharpened its focus on core hearing solutions. By contrast, Sonova's potential sale of its consumer electronics arm would represent a more radical decoupling from a non-core, high-growth but capital-intensive segment. The focus would then shift explicitly to premium headphones and soundbars with its consumer brand Sennheiser, but likely through a licensing model rather than direct ownership. This would preserve the brand's premium positioning while freeing up significant capital and management bandwidth.

For the market, this is a classic expectation reset. The acquisition was initially seen as a growth catalyst, but its integration has coincided with a period of market normalization and internal leadership change. Selling the unit would directly address the core growth concerns by eliminating a drag on capital allocation and simplifying the business. It's a move that tests whether Sonova can now focus on executing its hearing care strategy without the distraction of a complex consumer electronics operation. The upcoming strategy update on March 23 will be the first concrete test of this new direction.

Market Normalization and Forward Guidance

The forward narrative is now one of deliberate recalibration. CEO Eric Bernard has set a clear timeline for the market's return to normalcy, stating that growth rates in the hearing aid market will normalize towards the end of the year or in early 2027. This is the new baseline. It implies that the period of sluggish sales, which pressured Sonova's own growth and forced the guidance reset, is expected to persist through the first half of 2026. For investors, this means the expectation gap is not closing immediately. The market's whisper number for near-term hearing aid growth is being reset downward, aligning with management's view of a prolonged normalization.

The next catalyst to test this new reality is the company's strategy update on March 23. This event is critical. It will be the first formal opportunity for Sonova to articulate the results of its midterm review, including the fate of the Sennheiser consumer unit and the specific levers it plans to pull to navigate the normalized market. The update will either validate the current cautious path or introduce a sharper strategic pivot, directly impacting the forward earnings trajectory.

Within this reset, the focus on premium headphones and soundbars with the Sennheiser brand suggests a continued push into higher-margin consumer audio. However, the strategic review explicitly questions the standalone value of that business. This creates a tension: Sonova wants the premium positioning and margins, but may no longer want the operational and capital burden of owning it outright. The March 23 update will clarify whether the plan is to sell, license, or restructure this segment to fund the core hearing care business through the normalization period. The path forward is now contingent on that decision.